» Articles » PMID: 9949186

Oncostatin M Production and Regulation by Human Polymorphonuclear Neutrophils

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1999 Feb 9
PMID 9949186
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Oncostatin M (OSM) is an interleukin-6 (IL-6) family cytokine known in particular to induce the synthesis of acute-phase proteins by hepatocytes. Because human polymorphonuclear neutrophils (PMN) can secrete numerous cytokines, the potential production of OSM by PMN was investigated. Highly purified PMN were found to contain an intracellular stock of preformed OSM that was rapidly mobilized by degranulating agents such as phorbol myristate acetate and granulocyte-macrophage colony-stimulating factor (GM-CSF). Moreover, PMN produced OSM after a few hours of stimulation by various agonists. The most potent effect was observed with the combination of lipopolysaccharide and GM-CSF, which had a concentration- and time-dependent effect at both the protein and mRNA levels. Actinomycin D strongly reduced OSM mRNA induction, suggesting the involvement of gene transcription. Cycloheximide inhibited OSM protein synthesis but did not affect the release of preformed stores. In addition, OSM production was downregulated by dexamethasone, whereas IL-10 had no effect. The OSM produced by PMN was biologically active, as demonstrated by its ability to induce alpha1-acid glycoprotein synthesis by HepG2 cells. OSM secretion thus occurs through a two-step mechanism in PMN, consisting of early release of a preformed stock, followed by de novo protein synthesis. This would allow rapid and sustained OSM release to occur at inflammatory sites, and may contribute to the modulation of local inflammation.

Citing Articles

Naringenin, a Food Bioactive Compound, Reduces Oncostatin M Through Blockade of PI3K/Akt/NF-κB Signal Pathway in Neutrophil-like Differentiated HL-60 Cells.

Han N, Park H, Ko S, Moon P Foods. 2025; 14(1.

PMID: 39796391 PMC: 11719654. DOI: 10.3390/foods14010102.


Targeting Oncostatin M Receptor to Attenuate Carotid Artery Plaque Vulnerability in Hypercholesterolemic Microswine.

Trinh J, Shin J, Rai V, Agrawal D Cardiol Cardiovasc Med. 2024; 8(3):206-214.

PMID: 38817407 PMC: 11138392. DOI: 10.26502/fccm.92920380.


Additional Benefits of Serum Oncostatin M Levels Compared to Cardiac Troponin in Non-ST Elevation Myocardial Infarction.

Akarsu M, Atici A, Yoldemir S, Ozcan M, Yildirim O, Akarsu H Acta Cardiol Sin. 2024; 40(3):281-291.

PMID: 38779167 PMC: 11106615. DOI: 10.6515/ACS.202405_40(3).20240128A.


TGF-β1 activates neutrophil signaling and gene expression but not migration.

Hein L, SenGupta S, Gunasekaran G, Johnson C, Parent C PLoS One. 2023; 18(9):e0290886.

PMID: 37682817 PMC: 10490904. DOI: 10.1371/journal.pone.0290886.


Oncostatin M, Serpins, and Oxidative Stress in Extracellular Matrix Remodeling and Arteriovenous Fistula Maturation.

DeMarco N, Rai V, Wilson D, Agrawal D Cardiol Cardiovasc Med. 2023; 7(2):129-140.

PMID: 37484520 PMC: 10361734. DOI: 10.26502/fccm.92920318.